1. Pregnane X-receptor promotes stem cell-mediated colon cancer relapse
- Author
-
J. Ripoche, Daniel Brown, Fatemeh Rajabi, Véronique Garambois, Bertrand Beucher, Antoni Castells, Frédéric Hollande, Meritxell Gironella, Pascal Finetti, Julie Giraud, Jovana Kantar, André Pèlegrin, Charles Vincent, Julie Pannequin, Jean-Marc Pascussi, Ludovic Caillo, Jean-François Bourgaux, Michel Prudhomme, François Bertucci, Juan José Lozano, Christophe Ginestier, Fanny Grillet, Chris Planque, Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Institut d'Investigaciones Biomèdiques August Pi i Sunye (IDIBAPS), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Melbourne, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Ginestier, Christophe, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0301 basic medicine ,Male ,Receptors, Steroid ,Colorectal cancer ,Cohort Studies ,Mice ,Medicine ,Pregnane X receptor ,Mice, Inbred BALB C ,Pregnane X Receptor ,Prognosis ,3. Good health ,Oncology ,Colonic Neoplasms ,Neoplastic Stem Cells ,[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,Female ,Stem cell ,Research Paper ,cancer stem cell ,PXR ,Mice, Nude ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,colorectal cancer ,Antineoplastic Agents ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,digestive system ,Aldehyde Dehydrogenase 1 Family ,Disease-Free Survival ,03 medical and health sciences ,Breast cancer ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Side population ,Cancer stem cell ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,Spheroids, Cellular ,Biomarkers, Tumor ,Gene silencing ,Animals ,Humans ,[SDV.BC] Life Sciences [q-bio]/Cellular Biology ,Aged ,business.industry ,Retinal Dehydrogenase ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Aldehyde Dehydrogenase ,medicine.disease ,tumor recurrence ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,digestive system diseases ,030104 developmental biology ,Nuclear receptor ,Drug Resistance, Neoplasm ,Cancer research ,Neoplasm Recurrence, Local ,business ,Neoplasm Transplantation - Abstract
International audience; Colorectal cancer lethality usually results from post-treatment relapse in the majority of stage II-IV patients, due to the enhanced resistance of Cancer Stem Cells (CSCs). Here, we show that the nuclear receptor Pregnane X Receptor (PXR, NR1I2), behaves as a key driver of CSC-mediated tumor recurrence. First, PXR is specifically expressed in CSCs, where it drives the expression of genes involved in self-renewal and chemoresistance. Clinically, high levels of PXR correlate with poor recurrence-free survival in a cohort of >200 stage II/III colorectal cancer patients treated with chemotherapy, for whom finding biomarkers of treatment outcome is an urgent clinical need. shRNA silencing of PXR increased the chemo-sensitivity of human colon CSCs, reduced their self-renewal and tumor-initiating potential, and drastically delayed tumor recurrence in mice following chemotherapy. This study uncovers PXR as a key factor for CSC self-renewal and chemoresistance and targeting PXR thus represents a promising strategy to minimize colorectal cancer relapse by selectively sensitizing CSCs to chemotherapy.
- Published
- 2016
- Full Text
- View/download PDF